Initiating or switching to IDegAsp in a real-world South African population with type 2 diabetes – a cohort analysis from the ARISE study-Reference-Cited by-同舟云学术

Initiating or switching to IDegAsp in a real-world South African population with type 2 diabetes – a cohort analysis from the ARISE study

Published:2023-05-19 Issue:3 Volume:28 Page:92-99
ISSN:1608-9677
Container-title:Journal of Endocrinology, Metabolism and Diabetes of South Africa
language:en
Short-container-title:Journal of Endocrinology, Metabolism and Diabetes of South Africa

Author:

Kok Adri¹,Makan Hemant²,Podgorski Gracjan Piotr³,Joshi Shaifali⁴,Chetty Verushka⁵,Nojoko Lungisa⁶,Bacus Hajira⁷,Moosa Naeem⁸,Khutsoane Duma⁹

Affiliation:

1. Netcare Union Alberton Hospital, Alberton, South Africa

2. Centre for Diabetes, Lenasia, South Africa

3. Netcare Greenacres Hospital, Port Elizabeth, South Africa

4. Diabetes Care Centre, Brooklyn, South Africa

5. Novo Nordisk, Johannesburg, South Africa

6. PPMR-Clinical Trial Centre, ProHealth & Wellness Centre for Integrative Medicine, Port Elizabeth, South Africa

7. Lenmed Health Shifa Hospital, Durban, South Africa

8. General Practice, Lenasia, South Africa

9. Bloemfontein Mediclinic, Bloemfontein, South Africa

Funder

Novo Nordisk

Clinical Research Organisation

Publisher

Informa UK Limited

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/16089677.2023.2198348

Reference33 articles.

1. Society for Endocrinology, Metabolism and Diabetes of South Africa type 2 diabetes guidelines expert committee. Epidemiology of type 2 diabetes. In: 2017 SEMDSA Guideline for the Management of Type 2 Diabetes Guideline Committee. J Endocrinol Metab Diab SA. 2017;21(1)(Supplement 1):S1–S196.

2. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

3. U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease

4. β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes

5. Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49)